The Asia Pacific Body Fluid Collection And Diagnostics Market would witness market growth of 7.4% CAGR during the forecast period (2022-2028).
The examination of body fluid performs a crucial role in the diagnosis and prognosis of a disease. A physiological or pathological condition is indicated by a change in the concentration or content of a certain biochemical ingredient in body fluids. A specific component in human body fluids can be observed as a marker for the identification of a disease.
Detection of these types of markers in an early phase can cause a rise in diagnosis, which can allow the start of necessary therapeutic treatment. The tracking of a specific chemical species throughout the course of disease among the endogenous or exogenous compounds can further provide details regarding the effectiveness of a specific therapy.
The number of people participating in the basic old-age insurance scheme across China had reached 175 million, out of which 43.67 million were retirees, by the end of 2005. The total spending of the old-age insurance fund was 404 billion yuan. The state has also set up an adjustment mechanism for the basic pension by which the state adjusts the level of the basic pension of enterprise retirees in light of price fluctuations & wage raises of enterprise employees. The high old age funds and the rising geriatric population will propel the healthcare spending from this age group. Thus, with the rising number of old aged population, the market for body fluid collection and diagnostics market in the Asia Pacific region.
The China market dominated the Asia Pacific Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,861.8 million by 2028. The Japan market is estimated to grow a CAGR of 6.8% during (2022 - 2028). Additionally, The India market would experience a CAGR of 8.1% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
The examination of body fluid performs a crucial role in the diagnosis and prognosis of a disease. A physiological or pathological condition is indicated by a change in the concentration or content of a certain biochemical ingredient in body fluids. A specific component in human body fluids can be observed as a marker for the identification of a disease.
Detection of these types of markers in an early phase can cause a rise in diagnosis, which can allow the start of necessary therapeutic treatment. The tracking of a specific chemical species throughout the course of disease among the endogenous or exogenous compounds can further provide details regarding the effectiveness of a specific therapy.
The number of people participating in the basic old-age insurance scheme across China had reached 175 million, out of which 43.67 million were retirees, by the end of 2005. The total spending of the old-age insurance fund was 404 billion yuan. The state has also set up an adjustment mechanism for the basic pension by which the state adjusts the level of the basic pension of enterprise retirees in light of price fluctuations & wage raises of enterprise employees. The high old age funds and the rising geriatric population will propel the healthcare spending from this age group. Thus, with the rising number of old aged population, the market for body fluid collection and diagnostics market in the Asia Pacific region.
The China market dominated the Asia Pacific Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,861.8 million by 2028. The Japan market is estimated to grow a CAGR of 6.8% during (2022 - 2028). Additionally, The India market would experience a CAGR of 8.1% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Kits & Consumables
- Instruments
- Tests/Services
By Technology
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Fluorescence in situ hybridization (FISH)
- Others
By Sample Type
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
By Application
- Diagnostics & Monitoring
- Therapeutic Decision Making
- Prognostics & Screening
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Bio-Rad Laboratories, Inc
- Illumina, Inc
- Qiagen N.V
- Johnson & Johnson
- F.Hoffmann-La Roche Ltd
- Laboratory Corporation of America Holdings
- Biocept, Inc
- MDxHealth SA
- Guardant Health, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Body Fluid Collection And Diagnostics Market, by Product
1.4.2 Asia Pacific Body Fluid Collection And Diagnostics Market, by Technology
1.4.3 Asia Pacific Body Fluid Collection And Diagnostics Market, by Sample Type
1.4.4 Asia Pacific Body Fluid Collection And Diagnostics Market, by Application
1.4.5 Asia Pacific Body Fluid Collection And Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2021, Jan - 2022, Sep) Leading Players
Chapter 4. Asia Pacific Body Fluid Collection And Diagnostics Market by Product
4.1 Asia Pacific Kits & Consumables Market by Country
4.2 Asia Pacific Instruments Market by Country
4.3 Asia Pacific Tests/Services Market by Country
Chapter 5. Asia Pacific Body Fluid Collection And Diagnostics Market by Technology
5.1 Asia Pacific Polymerase Chain Reaction (PCR) Market by Country
5.2 Asia Pacific Next Generation Sequencing (NGS) Market by Country
5.3 Asia Pacific Fluorescence in situ hybridization (FISH) Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Body Fluid Collection And Diagnostics Market by Sample Type
6.1 Asia Pacific Blood Market by Country
6.2 Asia Pacific Urine Market by Country
6.3 Asia Pacific Saliva Market by Country
6.4 Asia Pacific Cerebrospinal Fluid Market by Country
Chapter 7. Asia Pacific Body Fluid Collection And Diagnostics Market by Application
7.1 Asia Pacific Diagnostics & Monitoring Market by Country
7.2 Asia Pacific Therapeutic Decision Making Market by Country
7.3 Asia Pacific Prognostics & Screening Market by Country
Chapter 8. Asia Pacific Body Fluid Collection And Diagnostics Market by Country
8.1 China Body Fluid Collection And Diagnostics Market
8.1.1 China Body Fluid Collection And Diagnostics Market by Product
8.1.2 China Body Fluid Collection And Diagnostics Market by Technology
8.1.3 China Body Fluid Collection And Diagnostics Market by Sample Type
8.1.4 China Body Fluid Collection And Diagnostics Market by Application
8.2 Japan Body Fluid Collection And Diagnostics Market
8.2.1 Japan Body Fluid Collection And Diagnostics Market by Product
8.2.2 Japan Body Fluid Collection And Diagnostics Market by Technology
8.2.3 Japan Body Fluid Collection And Diagnostics Market by Sample Type
8.2.4 Japan Body Fluid Collection And Diagnostics Market by Application
8.3 India Body Fluid Collection And Diagnostics Market
8.3.1 India Body Fluid Collection And Diagnostics Market by Product
8.3.2 India Body Fluid Collection And Diagnostics Market by Technology
8.3.3 India Body Fluid Collection And Diagnostics Market by Sample Type
8.3.4 India Body Fluid Collection And Diagnostics Market by Application
8.4 South Korea Body Fluid Collection And Diagnostics Market
8.4.1 South Korea Body Fluid Collection And Diagnostics Market by Product
8.4.2 South Korea Body Fluid Collection And Diagnostics Market by Technology
8.4.3 South Korea Body Fluid Collection And Diagnostics Market by Sample Type
8.4.4 South Korea Body Fluid Collection And Diagnostics Market by Application
8.5 Singapore Body Fluid Collection And Diagnostics Market
8.5.1 Singapore Body Fluid Collection And Diagnostics Market by Product
8.5.2 Singapore Body Fluid Collection And Diagnostics Market by Technology
8.5.3 Singapore Body Fluid Collection And Diagnostics Market by Sample Type
8.5.4 Singapore Body Fluid Collection And Diagnostics Market by Application
8.6 Malaysia Body Fluid Collection And Diagnostics Market
8.6.1 Malaysia Body Fluid Collection And Diagnostics Market by Product
8.6.2 Malaysia Body Fluid Collection And Diagnostics Market by Technology
8.6.3 Malaysia Body Fluid Collection And Diagnostics Market by Sample Type
8.6.4 Malaysia Body Fluid Collection And Diagnostics Market by Application
8.7 Rest of Asia Pacific Body Fluid Collection And Diagnostics Market
8.7.1 Rest of Asia Pacific Body Fluid Collection And Diagnostics Market by Product
8.7.2 Rest of Asia Pacific Body Fluid Collection And Diagnostics Market by Technology
8.7.3 Rest of Asia Pacific Body Fluid Collection And Diagnostics Market by Sample Type
8.7.4 Rest of Asia Pacific Body Fluid Collection And Diagnostics Market by Application
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Product Launches and Product Expansions:
9.1.5.3 Acquisition and Mergers:
9.2 Guardant Health, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.2.5.3 Acquisition and Mergers:
9.3 Illumina, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Acquisition and Mergers:
9.4 Qiagen N.V.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Acquisition and Mergers:
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.5.2 Product Launches and Product Expansions:
9.6 F. Hoffmann-La Roche Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Product Launches and Product Expansions:
9.7 Laboratory Corporation of America Holdings
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental Analysis
9.7.4 Recent strategies and developments:
9.7.4.1 Partnerships, Collaborations, and Agreements:
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.9 Biocept, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Product Launches and Product Expansions:
9.10. MDxHealth SA
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Qiagen N.V.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings
- Biocept, Inc.
- MDxHealth SA
- Guardant Health, Inc.
Methodology
LOADING...
